Paysign, Inc. Awarded 132 Plasma Centers for Immediate Transition

The Additions Significantly Increase the Company’s U.S. Plasma Market Share

Paysign, Inc. (NASDAQ: PAYS), a leading provider of patient affordability solutions, financial technology products, and integrated payment processing services, today announced that it has been awarded 132 established plasma donation centers through an expansion of its long-standing relationship with a major plasma collection company. Transition of the centers from the incumbent provider is underway, with 123 centers expected to be live by the end of the second quarter of 2025 and the remaining nine slated for transition during the third quarter of 2025.

“The addition of these centers underscores the strengths of the Paysign donor compensation platform and our ongoing investment in the plasma industry, as well as the hard work and dedication of the entire Paysign team,” said Mark Newcomer, President and CEO of Paysign. “This expansion once again reflects the confidence our clients, partners and customers have in our ability to deliver reliable, scalable and innovative solutions. It also reaffirms our position as a trusted partner to the plasma industry, where maximizing the donor experience is paramount.”

With the addition of these centers, Paysign will be providing donor compensation programs to more than 615 plasma centers across 18 plasma collection companies, increasing the number of centers the company supports by 27% and bringing its U.S. market share to approximately 50%. The additional centers will drive immediate revenue growth for Paysign’s plasma business.

Following onboarding, the centers are expected to reach approximately 80% of Paysign’s average revenue per center within the first few weeks and reach full revenue contribution by the end of the first quarter of 2026. Notably, the company does not anticipate a corresponding increase in Selling, General and Administrative (SG&A) expenses related to these new centers, highlighting the operating leverage inherent in its business model.

Forward-Looking Statements

Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934 and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the companies, are forward-looking statements that involve risks and uncertainties. There is no assurance that such statements will prove to be accurate, and actual results and future events could differ materially. Paysign undertakes no obligation to publicly update or revise any statements in this release, whether as a result of new information, future events or otherwise.

About Paysign

Paysign, Inc. is a leading provider of prepaid card programs, comprehensive patient affordability offerings, financial technology products and integrated payment processing designed for businesses, consumers and government institutions. Incorporated in 1995 and headquartered in southern Nevada, the company creates customized, innovative payment solutions for clients across all industries, including pharmaceutical, healthcare, hospitality, and retail. Built on the foundation of a reliable payments platform, Paysign’s end-to-end technologies securely enable digital payout solutions and facilitate the distribution of funds for donor compensation, copay assistance, customer incentives, employee rewards, travel expenses, per diem, reimbursements, rebates, and countless other exchanges of value. Paysign’s solutions lower costs, streamline operations and improve customer, employee and partner loyalty. To learn more, visit paysign.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250605055513/en/

The addition of these centers underscores the strengths of the Paysign donor compensation platform and our ongoing investment in the plasma industry.